Literature DB >> 6227748

Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers.

C A Demerson, L G Humber, N A Abraham, G Schilling, R R Martel, C Pace-Asciak.   

Abstract

Etodolac, 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid, a clinically effective analgesic and antiinflammatory agent, has been resolved via a chromatographic separation of its diastereoisomeric esters with (-)-borneol. The effects of the enantiomers were studied in vitro on prostaglandin synthetase and on adjuvant-induced arthritis in rats. The biochemical and pharmacological results show that virtually all of the effects of etodolac are due to the (+) enantiomer.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6227748     DOI： 10.1021/jm00366a025

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  14 in total

Review 1.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Authors:  Markus Jensen; Andreas Engert; Florian Weissinger; Wolfgang Knauf; Eva Kimby; Christopher Poynton; Ira Anton Oliff; Mathias J Rummel; Anders Osterborg
Journal:  Invest New Drugs       Date:  2007-12-20       Impact factor: 3.850

3.  R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.

Authors:  Jaideep Behari; Gang Zeng; Wade Otruba; Michael D Thompson; Peggy Muller; Amanda Micsenyi; Sandeep S Sekhon; Lorenzo Leoni; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2006-12-21       Impact factor: 25.083

Review 4.  Enantiomeric resolution of drug compounds by liquid chromatography.

Authors:  H T Karnes; M A Sarkar
Journal:  Pharm Res       Date:  1987-08       Impact factor: 4.200

5.  Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.

Authors:  Carolina de Miranda Silva; Adriana Rocha; Eduardo Tozatto; Lucienir Maria da Silva; Eduardo Antônio Donadi; Teresa Dalla Costa; Vera Lucia Lanchote; Stephan Schmidt; Jürgen B Bulitta
Journal:  AAPS J       Date:  2017-09-05       Impact factor: 4.009

6.  SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

Authors:  Hiroshi Yasui; Teru Hideshima; Makoto Hamasaki; Aldo M Roccaro; Norihiko Shiraishi; Shaji Kumar; Pierfrancesco Tassone; Kenji Ishitsuka; Noopur Raje; Yu-Tzu Tai; Klaus Podar; Dharminder Chauhan; Lorenzo M Leoni; Sarath Kanekal; Gary Elliott; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2005-03-31       Impact factor: 22.113

Review 7.  Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy.

Authors:  K McCormack; K Brune
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

8.  Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs.

Authors:  Desheng Lu; Howard B Cottam; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

9.  Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.

Authors:  Desheng Lu; Yandong Zhao; Rommel Tawatao; Howard B Cottam; Malini Sen; Lorenzo M Leoni; Thomas J Kipps; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

Review 10.  Etodolac clinical pharmacokinetics.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.